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Summary Interleukin-2 receptor (IL-2R) can be detected in serum. We estimated the IL-2R in the serum of
78 women, of whom 30 were diagnosed as having malignant ovarian tumours, five had non ovarian tumours,
one had a negative second look laparotomy, 11 had benign ovarian tumours, three had uterine fibroids and 28
were age-matched controls. The results indicated that the serum IL-2R of these patients was significantly
elevated in ovarian cancer patients compared to both controls (P<0.0001) and benign ovarian tumours
(P< 0.0002). There were no significant differences in IL-2R levels between stage of disease and degree of
differentiation within the ovarian tumour group.
Different parameters have been used to predict survival in
many solid tumours including ovarian cancer. Recently
elements of the immune system have also been considered.
One of the most frequently reported immune dysfunctions in
patients with disseminated solid neoplasms is reduced
interleukin-2 (IL-2) production (Nakayama et al., 1983;
Mantovani et al., 1986; Wanebo et al., 1986). IL-2 is a
glycoprotein of molecular weight approximately 15 kD. It is
produced from lectin- or antigen-activated T cells, and has a
number of functions, the most important being the stimula-
tion of antigen-activated T cell proliferation (Smith, 1988).
The high affinity IL-2 receptor (IL-2R) is composed of two
non-covalently linked subunits with molecular weights of
55 kD and 75 kD. Each is able to bind IL-2 with low affinity,
but the complex allows binding to IL-2 to occur rapidly and
dissociate very slowly. Signal transduction occurs solely via
the 75 kD molecule, whereas the 55 kD molecule appears to
act by aiding IL-2 binding (Kelly et al., 1990). The IL-2R is
the protein that mediates the action of IL-2. Normal resting
B and T cells do not normally display significant numbers of
these receptors on the cell surface (Robb et al., 1981; Mizel,
1989). However, when such cells are stimulated by a
challenge to the immune system, expression of IL-2R changes
in two ways: some molecules of IL-2R are expressed on the
plasma membrane and a form of IL-2R protein is released by
the activated cells.
Recently serum IL-2R levels have been found to predict
prognosis in patients with malignant disease. Lauria et al.
(1992) found that patients with low levels of serum IL-2R at
the time of diagnosis of Hairy-Cell Leukaemia (HCL) have a
better chance of achieving a good clinical response while
Fierro et al. (1992) estimated soluble IL-2R in 227 melanoma
patients and found values in all stages significantly higher
than in normal controls. Moreover these values correlated
with disease progression. To date IL-2R has been evaluated
extensively in haematological malignancies, but seldom in
ovarian cancer. Kikuchi et al. (1988) studied IL-2 production
by peripheral blood lymphocytes in advanced ovarian cancer
during the course of combination chemotherapy. IL-2 levels
were depressed but after addition of cimetidine, IL-2 produc-
tion was restored. They found no difference between IL-2R
expression in malignant compared to benign ovarian
tumours. In the present study we compare serum IL-2R
levels in patients with malignant ovarian tumours, normal
ovaries and benign ovarian tumours.
Materials and methods
Patient selection and serum collection
Patients were recruited prospectively on the basis of a pre-
operative clinical diagnosis of either malignant or benign
ovarian tumour. All tumours were staged in accordance with
FIGO classification (Shepherd, 1989) and subsequently
classified in accordance with Serov et al. (1973) by a single
pathologist. Age matched controls were identified pre-
operatively in patients undergoing hysterectomy for benign
conditions (usually menorrhagia) and their ovaries were all
normal macroscopically. Ethical approval was obtained by
the local ethical committee.
Ten ml of blood was taken pre-operatively or after clinical
examination in the controls. Blood was centrifuged at 800 g
for 10 min and serum was stored at - 20°C until required for
the IL-2R assay.
IL-2 receptor assay
This was measured using a sandwich enzyme immunoassay
kit (Laboratory Impex Ltd). The detection limit of the assay
is 50 u ml-' and the intra and interassay co-efficient of
precision are 3.4% and 5.6% respectively.
Statistical analysis
Wilcoxon and Mann-Whitney non parametric testing and
Spearmans and Kendals regression analysis were used
(Kmietowicz & Yannoulis, 1976).
Results
Seventy-eight patients were available for analysis and com-
prised the following groups which are illustrated in Tables Ia
and Ib: 30 patients with primary malignant ovarian tumours,
five non ovarian cancer patients and one patient undergoing
second look laparatomy (denoted by 'other' in Table Ta and
Figure 1), 11 benign ovarian tumours, three uterine fibroids
and 28 aged matched controls. For convenience the second
look laparotomy is included in the 'other' group as this
patient had received chemotherapy and all her biopsies were
benign.
The 30 malignant ovarian tumours were subdivided with
regard to stage and degree of differentiation as illustrated in
Table Ta.
Figure 1 illustrates the distribution of the IL-2R levels. In
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the malignant ovarian tumour group the IL-2 levels ranged
from 402 to 4,495 units ml-' (U ml-') with a median value of
1,267 U ml-'. In the patients with benign ovarian tumours
values ranged from 323-1,534 U ml-' with a median of
545 U ml-' while values in the control patients ranged from
309-1,177 U ml-' with a median of 567 U ml-'. IL-2R levels
were significantly elevated in the malignant group compared
to the control group (P<0.0001), and the malignant group
compared to the benign group (P<0.0002). There was no
significant difference between the control group and benign
ovarian tumour group.
There was no significant difference in IL-2R levels depend-
ing on stage-and degree of differentiation in the malignant
ovarian tumour group using Spearmans and Kendals regres-
sion analysis.
Discussion
Kikuchi et al. (1988) found no difference in IL-2R levels
between patients with benign tumours and those with ovarian
carcinoma, but studied IL-2R expression in peripheral blood
lymphocytes rather than serum as in this paper. This group
also observed no change in IL-2R following chemotherapy
and suggested that this may occur due to a decrease in IL-2
production and concomitant induction of IL-2R expression.
Possibly the continued presence of tumour antigens could
also explain this (Millis & Paetkau, 1980).
In contrast the results of Rovelli et al. (1988) agree with
ours. In their study serum IL-2R levels were significantly
higher in patients with malignant disease (mostly of breast
and lung) than in normal subjects. Patients with metastatic
solid tumours showed significantly higher mean levels than
those with malignancy but without metastases, and similar to
levels observed in the lymphoma patients. Interestingly,
Lotze et al. (1987) found high levels of IL-2R positive lym-
phocytes in peripheral blood of patients with malignant
tumours receiving recombinant IL-2.
This study has shown that IL-2R levels are significantly
raised in patients with malignant ovarian tumours relative to
normal controls. As this soluble IL-2R can bind interleukin-
2, it may have an immunoregulatory role by competing with
cellular IL-2R for the ligand and therefore down regulating
the immune response. We found no correlation between IL-
2R levels and disease staging or differentiation, or tumour
bulk.
It was surprising to find that the IL-2R levels in the fibroid
group were considerably higher than expected when com-
pared to both controls and the benign ovarian tumour group.
This could partly be explained by the fact that leiomyoma
cells contain a stress responsive protein (SRP27) and also
oestrogen and progesterone receptors which together have
immunological properties similar to cancer cell lines
(Navarro et al., 1989). Fibroids have also been shown to
produce erythropoietin suggesting that they have some
immunological role. Further measurement of IL-2R levels in
Table Ia Epidemological data of patients
IL-2R
Groups Age Histological type Stage Differentiation (U ml)'
Malignant ovarian tumours
69 Serous 3 WD 4495
66 Serous 4 WD 853
62 Serous 3 WD 553
79 Serous 3 MD 1403
78 Serous 3 MD 3711
68 Serous 4 MD 2592
54 Serous 3 MD 1964
47 Serous 3 MD 3524
54 Serous 3 MD 718
68 Serous IC MD 1045
46 Serous IA MD 800
67 Serous 2A PD 1806
79 Serous 4 PD 842
60 Serous IC PD 1226
84 Serous 4 Unstated 1629
53 Clear cell 2B WD 402
61 Clear cell 2B MD 3076
62 Clear cell 4 MD 778
83 Mucinous 3 MD 2255
54 Mucinous 4 MD 679
79 Endometrioid IC WD 486
57 Endometrioid 3 PD 2514
54 Endometrioid 3 PD 1666
58 Undifferentiated 4 768
71 Undifferentiated 3 1647
67 Undifferentiated 4 788
69 Unclassified 3 1730
64 Unclassified 3 1309
74 Mixed mesodermal 3 594
28 Endodermal sinus 2B 959
60 Negative 2nd look laparotomy 910
Non ovarian tumours
69 Spindle cell low grade 1348
75 Bladder tumour 375
70 Caecal cancer 751
47 Metastatic breast 333
45 Fallopian tubal cancer 912
Abbreviations: WD: Well differentiated. MD: Moderately differentiated. PD: Poorly.
differentiated.
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Table lb Epidemological data of patients 5000-
IL-2R
Groups Age Histological type (U ml)-'
Benign 48 Teratoma 637
ovarian 76 Serous cystadenoma 323
tumours 74 Serous cystadenoma 404
35 Serous cystadenoma 4493000
51 Mucinous cystadenoma 638
71 Endometrioid borderline malignant 570 E
65 Fibroma 428 2000-
69 Fibroma 696
63 Fibroma 545
56 Simple cyst 1534 1000
62 Simple cyst 413
Fibroids 84 2577
59 2194 _
52 946 0- o ' t
Controls 89 1083 *> m 2 °
84 738 o a
81 1067
76 503 Figure 1 Distribution of IL-2R values in U ml-' for the five









50 416 patients with fibroids would be required to clarify this
48 309 point.
45 442 We will assess at a later date whether an incidental
41 467 measure of IL-2R pre-operatively has any bearing on long
40 400 term prognosis. As has been suggested by others (Waldmann
38 476 et al., 1992), patients with malignant disease who demon-
35 362 strate elevated IL-2R, may benefit therapeutically from IL-2.
35 515 We are currently assessing whether patients with ovarian
34 715 cancer have any alteration in thier IL-2R levels during
30 1177 chemotherapy or over the course of their disease.
29 880
27 375
21 775 This research was carried out with financial assistance from the20 982 Glasgow Royal Infirmary Gynaecology Oncology Fund.
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